ABSTRACT Objective To investigate the clinical value of real-time contrast-enhanced ultrasound guided monopolar radiofrequency ablation (M-RFA) and no-touch multipole radiofrequency ablation (No-touch RFA) in the treatment of liver tumors. Methods This study retrospectively analyzed 94 cases of liver tumors patients (including M-RFA methods 44 cases, No-touch RFA methods 50 cases) treated with M-RFA and no-touch RFA under the guidance of real-time CEUS in our hospital from February 2015 to May 2017. Postoperative lesion inactivation range, inactivation rate and complications were analyzed,and liver function,AFP, CEUS,enhanced CT and MRI before and after treatment were compared, and patients were followed up regularly for 24 months,the disease-free survival rate was followed. Results After RFA treatment, CEUS was used to measure the inactivation range. The average inactivation range of the M-RFA group and the No-touch RFA group was 38.36x31.31mm and 46.70x35.82mm, respectively. The total tumor necrosis rate was: 90.9% (40/44) and 98.00% (49/50), respectively, in the M-RFA group and the No-touch RFA group，the difference was statistically significant (P<0.05).In the M-RFA group, among 21 patients positive for AFP，12 cases were transferred into negative AFP and serum AFP level in 8 cases decreased significantly,In the No-touch RFA group, among 20 patients positive for AFP，14 cases were transferred into negative AFP and serum AFP level in 5 cases decreased significantly during the period of 1-6 months after RFA treatment,and the difference in AFP preoperative and postoperative levels between the two groups was statistically significant (P<0.05). Regular follow-up to 24 months after RFA treatment showed that the tumor-free survival rate was 47.72% (21/44) in the M-RFA group and 68.00% (34/50) in the No-touch RFA group, and the difference between the two groups was statistically significant (P < 0.05).Conclusion Real-time CEUS guided No-touch RFA treatment of liver tumors is helpful to improve the total tumor necrosis rate, with significant efficacy and high tumor-free survival rate, and has important application value.